Stakeholders concerned over Australian drug labelling and packaging proposals
This article was originally published in SRA
Proposals by Australia's Therapeutic Goods Administration to improve the labelling and packaging of medicines are of concern to stakeholders who fear the recommendations might be too prescriptive, inflexible and costly1.
You may also be interested in...
Zolgensma should receive a conditional approval, says the European Medicines Agency’s drug evaluation committee, the CHMP.
The health technology assessment institute is taking a virtual approach to meetings and has said that it can provide free fast-track advice for companies developing novel diagnostics or therapeutics for the coronavirus.
Companies are due to learn this week whether the European Medicines Agency will fast-track its review of their soon-to-be-filed EU marketing applications.